APA (7th ed.) Citation

W, W., J, W., T, G., X, W., M, Y., J, Z., . . . P, S. (2026). Identification of SLIT3 mutation as a response biomarker for immune checkpoint inhibitor therapy in non-small cell lung cancer. Discover oncology, 17(1), . https://doi.org/10.1007/s12672-026-04911-7

Chicago Style (17th ed.) Citation

W, Wang, Wang J, Ge T, Wang X, Yang M, Zhu J, Ji C, and Shu P. "Identification of SLIT3 Mutation as a Response Biomarker for Immune Checkpoint Inhibitor Therapy in Non-small Cell Lung Cancer." Discover Oncology 17, no. 1 (2026). https://doi.org/10.1007/s12672-026-04911-7.

MLA (9th ed.) Citation

W, Wang, et al. "Identification of SLIT3 Mutation as a Response Biomarker for Immune Checkpoint Inhibitor Therapy in Non-small Cell Lung Cancer." Discover Oncology, vol. 17, no. 1, 2026, https://doi.org/10.1007/s12672-026-04911-7.